<DOC>
	<DOC>NCT00219375</DOC>
	<brief_summary>The purpose of this study is to confirm the efficacy and safety of sivelestat in patients with acute lung injury associated with systemic inflammatory response syndrome. The results will be compared to the study with conventional treatment without sivelestat.</brief_summary>
	<brief_title>Study of Sivelestat Sodium Hydrate in Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS) in Japan</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Wounds and Injuries</mesh_term>
	<mesh_term>Acute Lung Injury</mesh_term>
	<mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
	<mesh_term>Lung Injury</mesh_term>
	<mesh_term>Systemic Inflammatory Response Syndrome</mesh_term>
	<mesh_term>Sivelestat</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>1. Patients with systemic inflammatory response syndrome (SIRS) 2. Patients with acute lung injury (ALI) assessed using the criteria specified by the AmericanEuropean Consensus Conference 3. Within 72 hours of onset of lung injury 4. Other inclusion criteria as specified in the protocol 1. Already administrated Sivelestat before enrollment in the study 2. Neuromuscular disease that impairs spontaneous ventilation 3. Severe central nervous system disease 4. Bone marrow transplant 5. Lung transplant 6. Severe chronic liver disease 7. Neutropenia (neutrophil count: below 1000/mm3) 8. Other exclusion criteria as specified in the protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>sivelestat sodium hydrate</keyword>
	<keyword>acute lung injury</keyword>
	<keyword>systemic inflammatory response syndrome</keyword>
	<keyword>Elaspol</keyword>
	<keyword>Acute Lung Injury (ALI) Associated With Systemic Inflammatory Response Syndrome (SIRS)</keyword>
</DOC>